ReviewRSC medicinal chemistry2022
Recent advancements in chromone as a privileged scaffold towards the development of small molecules for neurodegenerative therapeutics.
Review in RSC medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 51 citations in OpenAlex.
- Synthesis and multi-target evaluation of 2-(2-phenylethyl)/2,3-styrylchromone derivatives as potential anti-Alzheimer's disease agents.Molecular diversity · 2026Article
- A quarter-century journey into 4-chromone derivatives: synthesis, reactions, and pioneering applications thereof.RSC advances · 2026Review
- New benzochromene-based compounds as potential EGFR-TK inhibitors: synthesis, anti-proliferative activity, molecular docking studies, and ADME profiles.RSC advances · 2026Article
- Article
- Benzo[ACS omega · 2026Article
- Electrochemical Synthesis of 3-Selenyl-Chromones via Domino C(spMolecules (Basel, Switzerland) · 2026Article
- Potential of MAO-B Inhibitors with Multi-target Inhibition and Antioxidant Properties for the Treatment of Neurodegenerative Disorders.Mini reviews in medicinal chemistry · 2026Review
- Comprehensive Computational Study of a Novel Chromene-Trione Derivative Bioagent: Integrated Molecular Docking, Dynamics, Topology, and Quantum Chemical Analysis.International journal of molecular sciences · 2025Article
- Design, Synthesis and Biological Evaluation of Chromeno[3,4-ACS chemical neuroscience · 2025Article
- Design and synthesis of novel pyridopyrimidine moieties linked to coumarin ring of potentially active cytotoxic agents and their docking study.Scientific reports · 2025Article
- Synthesis and Biological Activity of Chromeno[3,2-Molecules (Basel, Switzerland) · 2024Review
- Review
- Domino reactions of chromones with activated carbonyl compounds.Beilstein journal of organic chemistry · 2024Review
- A Concise Review of the Recent Structural Explorations of Chromones as MAO-B Inhibitors: Update from 2017 to 2023.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Design, synthesis, and biological evaluation of morpholinopyrimidine derivatives as anti-inflammatory agents.RSC advances · 2023Article
- Chemical and Biological Evaluation of Novel 1International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative disorders,
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.